[1] |
Hasan S, Jamdar SF, Jangra J, et al. Oral malignant melanoma: an aggressive clinical entity--report of a rare case with review of literature[J]. J Int Soc Prev Community Dent, 2016, 6(2):176-181. doi: 10.4103/2231-0762.175145.
|
[2] |
LeeR J, Lee SA, Lin T, et al. Determining the epidemiologic, outcome, and prognostic factors of oral malignant melanoma by using the surveillance, epidemiology, and end results database[J]. J Am Dent Assoc, 2017, 148(5):288-297. doi: 10.1016/j.adaj.2017.01.019.
DOI
URL
|
[3] |
Ashok S, Damera S, Ganesh S, et al. Oral malignant melanoma[J]. J Oral Maxillofac Pathol, 2020, 24(Suppl1):S82-S85. doi: 10.4103/jomfp.
|
[4] |
Khanna P, Nigam JS, Kumar T, et al. Pigmented malignant lesion of central arch gingiva of mandible[J]. Cureus, 2020, 12(12):e12210. doi: 10.7759/cureus.12210.
|
[5] |
Singh D, Pandey P, Singh MK, et al. Prevalence of malignant melanoma in anatomical sites of the oral cavity: a meta-analysis[J]. J Oral Maxillofac Pathol, 2019, 23(1):129-135. doi: 10.4103/jomfp.JOMFP_236_18.
|
[6] |
Abu-Zaid A, Al-Zaher N. Primary oral malignant melanoma of the tongue[J]. N Z Med J, 2018, 131(1470):87-88.
|
[7] |
Aziz Z, Aboulouidad S, Bouihi ME, et al. Oral amelanotic malignant melanoma: a case report[J]. Pan Afr Med J, 2020, 37:350. doi: 10.11604/pamj.2020.37.350.27330.
|
[8] |
Sun S, Huang X, Gao L, et al. Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution[J]. Oral Oncol, 2017, 74:115-122. doi: 10.1016/j.oraloncology.2017.09.020.
DOI
URL
|
[9] |
杨溪, 张安玲, 张陈平, 等. 52例原发性口腔黏膜恶性黑色素瘤的临床分析[J]. 临床肿瘤学杂志, 2011, 16(10):882-886. doi: 10.3969/j.issn.1009-0460.2011.10.005.
|
|
Yang X, Zhang AL, Zhang CP, et al. Clinical analysis on 52 cases of primary oral mucosal melanoma[J]. Chin Clin Oncol, 2011, 16(10):882-886. doi: 10.3969/j.issn.1009-0460.2011.10.005.
|
[10] |
Hadash-Bengad R, Hajaj E, Klein S, et al. Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma--a retrospective study[J]. Front Oncol, 2020, 10:70. doi: 10.3389/fonc.2020.00070.
DOI
URL
PMID
|
[11] |
Bright R, Coventry BJ, Eardley-Harris N, et al. Clinical response rates from interleukin-2 therapy for metastatic melanoma over 30 years’ experience: a meta-analysis of 3312 patients[J]. J Immunother, 2017, 40(1):21-30. doi: 10.1097/cji.0000000000000149.
DOI
URL
|
[12] |
Onitilo AA, Wittig JA. Principles of immunotherapy in melanoma[J]. Surg Clin North Am, 2020, 100(1):161-173. doi: 10.1016/j.suc.2019.09.009.
DOI
URL
|
[13] |
Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2.
DOI
URL
|
[14] |
Depenni R. Treatment combinations in BRAF-mutant metastatic melanoma[J]. Recenti Prog Med, 2021, 112(4):40e-43e. doi: 10.1701/3584.35696.
|
[15] |
毛丽丽, 斯璐, 郭军. 2020版CSCO黑色素瘤指南解读[J]. 中华转移性肿瘤杂志, 2020, 3(2):81-82. doi: 10.3760/cma.j.cn101548-20200624-00082.
|
|
Mao LL, Si L, Guo J. Interpretation of CSCO melanoma guidelines 2020[J]. Chin J Metastatic Cancer, 2020, 3(2):81-82. doi: 10.3760/cma.j.cn101548-20200624-00082.
|